Maxcyte (MXCT) Return on Sales (2020 - 2026)

Maxcyte (MXCT) has 7 years of Return on Sales data on file, last reported at 0.01% in Q1 2026.

• On a quarterly basis, Return on Sales changed 0.0% year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.03%, a 1.0% decrease from a year earlier, with the FY2025 full-year figure at 0.02%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.01%, down from 0.02% in the prior quarter.
• Over the last five years, Return on Sales for MXCT reached as high as 0.02% in Q4 2025 and fell as low as 0.04% in Q4 2022.
• Historically, Return on Sales has averaged 0.02% across 5 years, with a median of 0.02% in 2024.
• Across the five-year window, Return on Sales slipped 3 bps in 2022 and advanced 4 bps in 2025, its largest moves.
• Year by year, Return on Sales stood at 0.04% in 2022, then surged by 95 bps to 0.0% in 2023, then tumbled by 780 bps to 0.02% in 2024, then surged by 215 bps to 0.02% in 2025, then slumped by 152 bps to 0.01% in 2026.
• Per Business Quant data, the three most recent Return on Sales figures were 0.01% in Q1 2026, 0.02% in Q4 2025, and 0.02% in Q3 2025.